Sodium glucose co-transporter 2 inhibitors in heart failure therapy

Sodium glucose co-transporter 2 inhibitors in heart failure therapy

Bibliographic Details
Main Authors:	Yüksel Çavuşoğlu, Hakan Altay, Avivit Cahn, Ahmet Celik, Serafettin Demir, Barış Kılıçaslan, Sanem Nalbantgil, Itamar Raz, Ahmet Temizhan, Özlem Yıldırımtürk, Mehmet Birhan Yılmaz
Format:	Article
Language:	English
Published:	KARE Publishing 2020-04-01
Series:	Türk Kardiyoloji Derneği Arşivi
Subjects:	sglt2 inhibitors heart failure diabetes mellitus
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-74332

Similar Items

How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?
by: Ahmet Çelik, et al.
Published: (2023-05-01)

Management of Hyperkalemia in Heart Failure
by: Hakan Altay, et al.
Published: (2021-10-01)

Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs
by: Yüksel Çavuşoğlu, et al.
Published: (2022-07-01)

Vaccination of adults with heart failure and chronic heart conditions: Expert opinion
by: Ahmet Çelik, et al.
Published: (2018-11-01)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022-02-01)

2016 ESC and ACC/AHA/HFSA heart failure guideline updates: Changes, similarities, differences, and unresolved isssues
by: İbrahim Sarı, et al.
Published: (2016-12-01)

Comparative study of sodium-dependent glucose co-transporters in kidneys of Ostrich chickens
by: Piret Hussar, et al.
Published: (2022-07-01)

Short Communication: Immunohistochemical study of sodium-dependent glucose co-transporters in ostriches kidneys
by: Piret Hussar, et al.
Published: (2020-12-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

Utilidade da Idade, Creatinina e Fração de Ejeção - Modificação da Dieta no Escore de Doença Renal para Prever a Sobrevivência em Pacientes com Insuficiência Cardíaca
by: Rengin Çetin Güvenç, et al.
Published: (2023-12-01)

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
by: Věra Čertíková Chábová, et al.
Published: (2022-03-01)

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
by: Jonali Ramani, et al.
Published: (2022-12-01)

Snapshot evaluation of heart failure in Turkey: Baseline characteristics of SELFIE-TR
by: Mehmet Birhan Yılmaz, et al.
Published: (2019-04-01)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01)

Sleeve Gastrectomy Surgery Improves Glucose Metabolism by Downregulating the Intestinal Expression of Sodium–Glucose Cotransporter-3
by: Yixing Ren, et al.
Published: (2022-01-01)

Noncompliance with Dietary Salt Restriction and Outcomes in Chronic Heart Failure: A Propensity Score Matching Analysis from TREAT-HF Registry
by: Bihter Senturk, et al.
Published: (2021-03-01)

Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
by: Piotr Londzin, et al.
Published: (2022-11-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

d-Allose is absorbed via sodium-dependent glucose cotransporter 1 (SGLT1) in the rat small intestine
by: Kunihiro Kishida, et al.
Published: (2021-09-01)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
by: Jennifer Matthews, et al.
Published: (2023-03-01)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
by: Hang-Long Li, et al.
Published: (2021-05-01)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
by: Victor Chien-Chia Wu, et al.
Published: (2021-07-01)

Sodium‐glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure
by: Patric Karlström, et al.
Published: (2024-02-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review
by: Rachel Porth, et al.
Published: (2024-02-01)

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
by: Koichiro Matsumura, et al.
Published: (2019-11-01)

Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
by: Humberto Reyes-Pardo, et al.
Published: (2019-08-01)

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
by: Francesca Romana Prandi, et al.
Published: (2022-09-01)

Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions
by: D'Elia JA, et al.
Published: (2017-06-01)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
by: Alex Ali Sayour, et al.
Published: (2020-09-01)

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01)

Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction
by: Sencer Çamcı, et al.
Published: (2022-08-01)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
by: Masahiko Iwamoto, et al.
Published: (2022-08-01)

Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice
by: Arturo Cesaro, et al.
Published: (2023-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Arjun K. Pandey, et al.
Published: (2021-09-01)

Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus
by: Mohammed Ali Gameil, et al.
Published: (2020-08-01)

The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model
by: Kyoung Ree Lim, et al.
Published: (2024-01-01)

Drug Therapies for Diabetes
by: Roni Weinberg Sibony, et al.
Published: (2023-12-01)